ArticleJournal of central nervous system disease2024

Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments.

Erwan Muros-Le Rouzic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.